Muhammad HendraIn an era defined by relentless demands and escalating stress, a surprisingly simple yet profound tool for fostering happiness and resilience is often overlooked: play. Elisha Goldstein, Ph.D., a distinguished…
Cintya Tara AnnisaThe long-standing debate over the optimal timing for caffeine consumption has reached a significant turning point following the publication of a comprehensive meta-analysis that challenges popular "biohacking" trends. For years,…
Susilo Wagino MulyoThe landscape of sleep apnea treatment is undergoing a significant transformation with the emergence of Glucagon-like peptide-1 receptor agonists (GLP-1s), a class of medications initially developed for type 2 diabetes.…
Hanik KholidahWhile the biological transition of menopause has historically been framed through the lens of reproductive cessation and symptomatic discomforts such as hot flashes and mood swings, contemporary medical science is…
Hanik KholidahThe landscape of preventative health has shifted significantly over the last decade, moving away from a "one-size-fits-all" approach toward targeted, bioavailable, and scientifically backed nutritional support. As modern lifestyles and…
Susilo Wagino MulyoThe landscape of treating Obstructive Sleep Apnea (OSA) is undergoing a significant transformation with the emergence of Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications initially developed for type…
Susilo Wagino MulyoThe U.S. Food and Drug Administration (FDA) has delivered a significant development in the treatment of obstructive sleep apnea (OSA), approving tirzepatide (Zepbound), a glucagon-like peptide-1 (GLP-1) receptor agonist, for…
Susilo Wagino MulyoThe treatment paradigm for obstructive sleep apnea (OSA) is undergoing a significant transformation with the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications initially developed for type…
Susilo Wagino MulyoThe landscape of managing obstructive sleep apnea (OSA) is undergoing a significant transformation, driven in part by the increasing use of Glucagon-like peptide-1 receptor agonists (GLP-1s). These medications, initially developed…
Susilo Wagino MulyoThe emergence of Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and the recently FDA-approved Zepbound, has opened new avenues in the treatment of obstructive sleep apnea (OSA), particularly for…
